GSE185160
JAML is a novel immunotherapy target for tissue-resident memory T cells [bulk RNA-seq]
Tumor-infiltrating CD8+ T cells express high levels of the co-stimulatory molecule JAML, which can be exploited for cancer immunotherapy. Overall design: Single-cell RNA-seq was performed from CD45+JAML+ T cells isolatied from murine tumor (n = 3); bulk RNA-seq of tumor-infiltrating CD4+FOXP3+ Treg cells and CD8+ T cells